# First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome

> **NCT03594955** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 7 (actual)

## Conditions studied

- Leukaemia

## Interventions

- **DRUG:** SAR440234

## Key facts

- **NCT ID:** NCT03594955
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-24
- **Primary completion:** 2021-02-06
- **Final completion:** 2021-02-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594955, "First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03594955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*